Menu
Search
|

Menu

Close
X

FibroGen Inc FGEN.OQ (NASDAQ Stock Exchange Global Select Market)

56.50 USD
+0.05 (+0.09%)
As of Feb 16
chart
Previous Close 56.45
Open 56.20
Volume 101,392
3m Avg Volume 194,788
Today’s High 57.15
Today’s Low 55.90
52 Week High 63.00
52 Week Low 22.80
Shares Outstanding (mil) 82.20
Market Capitalization (mil) 4,644.16
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.57 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY17
83
FY16
180
FY15
181
EPS (USD)
FY17
-1.492
FY16
-1.016
FY15
-1.530
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.43
Price to Sales (TTM)
vs sector
40.36
8.57
Price to Book (MRQ)
vs sector
8.09
5.14
Price to Cash Flow (TTM)
vs sector
--
25.75
Total Debt to Equity (MRQ)
vs sector
20.00
15.12
LT Debt to Equity (MRQ)
vs sector
20.00
11.85
Return on Investment (TTM)
vs sector
-22.78
13.54
Return on Equity (TTM)
vs sector
-36.83
14.80

EXECUTIVE LEADERSHIP

Thomas Neff
Chairman of the Board, Chief Executive Officer, Founder, Since
Salary: $805,000.00
Bonus: $583,223.00
Pat Cotroneo
Chief Financial Officer, Vice President - Finance, Since 2008
Salary: $440,000.00
Bonus: $233,772.00
Frank Valone
Senior Fellow, Clinical Development, Since 2016
Salary: $257,074.00
Bonus: --
K. Peony Yu
Chief Medical Officer, Since 2016
Salary: $463,000.00
Bonus: $245,992.00
Gerald Lema
Director, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

409 Illinois St
SAN FRANCISCO   CA   94158-2509

Phone: +1415.9781200

FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.

SPONSORED STORIES